AR017754A1 - Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento - Google Patents
Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamentoInfo
- Publication number
- AR017754A1 AR017754A1 ARP980103094A ARP980103094A AR017754A1 AR 017754 A1 AR017754 A1 AR 017754A1 AR P980103094 A ARP980103094 A AR P980103094A AR P980103094 A ARP980103094 A AR P980103094A AR 017754 A1 AR017754 A1 AR 017754A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- compound
- formula
- macrolidas
- cristalinas
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000002360 preparation method Methods 0.000 title abstract 4
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002425 crystallisation Methods 0.000 abstract 2
- 230000008025 crystallization Effects 0.000 abstract 2
- 239000006071 cream Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 239000003120 macrolide antibiotic agent Substances 0.000 abstract 1
- 229940041033 macrolides Drugs 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Metallurgy (AREA)
- Materials Engineering (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Macrolidas, que comprenden el compuesto de la formula (I) o una forma tautomérica o solvatada del mismo, en forma cristalina. su preparacion involucraconvertir apropiadamente el compuesto amorfo de la formula (I), o el compuesto de la formula (I) enuna forma diferente de la Forma A, o el compuesto de laformula (I) en una forma diferente de la Forma B, respectivamente, a partir de una solucion del mismo, bajo condiciones que induzcan cristalizacion, o bajocondiciones que induzcan cristalizacionpreferencial de la Forma A o B respectivamente. Estos cristales se indican particularmente para utilizarse en lapreparacion de formas galénicas locales del compuesto para uso farmacéutico, por ejemplo cremas, emulsiones, y unguentos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9713730.1A GB9713730D0 (en) | 1997-06-30 | 1997-06-30 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017754A1 true AR017754A1 (es) | 2001-10-24 |
Family
ID=10815103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980103094A AR017754A1 (es) | 1997-06-30 | 1998-06-26 | Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6423722B1 (es) |
| EP (1) | EP0994880B1 (es) |
| JP (2) | JP3880634B2 (es) |
| KR (1) | KR100399765B1 (es) |
| CN (1) | CN1139595C (es) |
| AR (1) | AR017754A1 (es) |
| AT (1) | ATE287410T1 (es) |
| AU (1) | AU739211B2 (es) |
| BR (1) | BR9810956A (es) |
| CA (1) | CA2290412C (es) |
| CO (1) | CO4940463A1 (es) |
| CZ (1) | CZ297244B6 (es) |
| DE (1) | DE69828692T2 (es) |
| DK (1) | DK0994880T3 (es) |
| ES (1) | ES2236922T3 (es) |
| GB (1) | GB9713730D0 (es) |
| HU (1) | HU227755B1 (es) |
| ID (1) | ID24897A (es) |
| IL (1) | IL132761A0 (es) |
| MY (1) | MY118718A (es) |
| NO (1) | NO312765B1 (es) |
| NZ (1) | NZ500994A (es) |
| PE (1) | PE97699A1 (es) |
| PL (1) | PL192761B1 (es) |
| PT (1) | PT994880E (es) |
| RU (1) | RU2219181C2 (es) |
| SK (1) | SK285665B6 (es) |
| TR (1) | TR199903189T2 (es) |
| TW (1) | TW552264B (es) |
| WO (1) | WO1999001458A1 (es) |
| ZA (1) | ZA985655B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9713730D0 (en) * | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| GB9826656D0 (en) | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| GB0125443D0 (en) * | 2001-10-23 | 2001-12-12 | Novartis Ag | Organic Compounds |
| ES2335284T3 (es) * | 2003-09-03 | 2010-03-24 | Glaxo Group Limited | Nuevo procedimiento para preparar derivados de pleuromutilina. |
| US9168224B2 (en) * | 2004-04-08 | 2015-10-27 | Meda Pharma Sarl | Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides |
| WO2006060615A1 (en) | 2004-12-01 | 2006-06-08 | Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg | Non-hygroscopic and powdery amorphous pimecrolimus |
| TW200837067A (en) * | 2006-11-06 | 2008-09-16 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof |
| EP2099298A4 (en) * | 2006-12-07 | 2010-01-06 | Helsinn Healthcare Sa | CRYSTALLINE AND AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE |
| US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
| EP2451496B1 (en) | 2009-07-10 | 2015-07-22 | Boston Scientific Scimed, Inc. | Use of nanocrystals for a drug delivery balloon |
| US10080821B2 (en) | 2009-07-17 | 2018-09-25 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
| WO2012031236A1 (en) | 2010-09-02 | 2012-03-08 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
| WO2013022458A1 (en) * | 2011-08-05 | 2013-02-14 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
| WO2013028208A1 (en) | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
| SG10202112135VA (en) * | 2013-03-15 | 2021-12-30 | Biosensors International Group Ltd | Purification of rapamycin derivatives |
| EP3178824A1 (en) | 2015-12-08 | 2017-06-14 | Medichem, S.A. | Process for preparing pimecrolimus |
| ES2906158T3 (es) * | 2017-05-01 | 2022-04-13 | Meda Pharma Gmbh & Co Kg | Proceso para convertir ascomicina bruta en pimecrolimus purificado |
| EP3741367A1 (en) | 2019-05-21 | 2020-11-25 | Premark Pharma GmbH | Treatment of ocular disease |
| EP4687895A1 (en) | 2023-04-06 | 2026-02-11 | Premark Pharma GmbH | Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51118816A (en) * | 1975-04-08 | 1976-10-19 | Meiji Seika Kaisha Ltd | A process for stabilizing non-crystalloidal solid |
| US4127647A (en) * | 1975-04-08 | 1978-11-28 | Meiji Seika Kaisha, Ltd. | Process for preparation of stable amorphous macrolide antibiotic solids |
| CY1306A (en) | 1980-10-01 | 1985-12-06 | Glaxo Group Ltd | Aminoalkyl furan derivative |
| JP2728482B2 (ja) * | 1989-01-26 | 1998-03-18 | 協和醗酵工業株式会社 | マクロライド系抗生物質の精製法 |
| JPH089630B2 (ja) | 1989-07-10 | 1996-01-31 | ヘマ・ソシエダード・アノニマ | 有機化合物の、または関連する改善 |
| DK0427680T3 (da) * | 1989-11-09 | 1995-12-18 | Sandoz Ltd | Heteroatom-holdige cykliske forbindelser |
| EP0594600A1 (en) * | 1990-03-13 | 1994-05-04 | FISONS plc | Immunosuppressive macrocyclic compounds |
| EP0480623A1 (en) * | 1990-10-11 | 1992-04-15 | Merck & Co. Inc. | New halomacrolides and derivatives having immunosuppressive activity |
| US5143918A (en) * | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
| DE10199058I2 (de) | 1991-07-30 | 2006-04-27 | Alcm Co | Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung |
| US5247076A (en) | 1991-09-09 | 1993-09-21 | Merck & Co., Inc. | Imidazolidyl macrolides having immunosuppressive activity |
| US5221740A (en) | 1992-01-16 | 1993-06-22 | American Home Products Corporation | Oxepane isomers of rapamycin useful as immunosuppressive agents |
| UA41884C2 (uk) * | 1993-11-05 | 2001-10-15 | Амерікан Хоум Продактс Корпорейшн | Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів |
| JP3808500B2 (ja) * | 1994-02-22 | 2006-08-09 | キューレータズ オブ ディ ユニバーシティ オブ ミズーリ | 分離剤としての大環状抗生物質 |
| CA2229718A1 (en) * | 1995-08-24 | 1997-03-06 | David J. Mathre | Process for the preparation of imidazolyl macrolide immunosuppressants |
| GB9713730D0 (en) * | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
-
1997
- 1997-06-30 GB GBGB9713730.1A patent/GB9713730D0/en active Pending
-
1998
- 1998-06-25 CO CO98036359A patent/CO4940463A1/es unknown
- 1998-06-26 CA CA002290412A patent/CA2290412C/en not_active Expired - Lifetime
- 1998-06-26 RU RU2000101826/04A patent/RU2219181C2/ru active
- 1998-06-26 TR TR1999/03189T patent/TR199903189T2/xx unknown
- 1998-06-26 HU HU0003053A patent/HU227755B1/hu unknown
- 1998-06-26 AU AU85409/98A patent/AU739211B2/en not_active Expired
- 1998-06-26 AR ARP980103094A patent/AR017754A1/es active IP Right Grant
- 1998-06-26 AT AT98936392T patent/ATE287410T1/de active
- 1998-06-26 CN CNB988064677A patent/CN1139595C/zh not_active Expired - Lifetime
- 1998-06-26 WO PCT/EP1998/003929 patent/WO1999001458A1/en not_active Ceased
- 1998-06-26 ES ES98936392T patent/ES2236922T3/es not_active Expired - Lifetime
- 1998-06-26 KR KR10-1999-7010048A patent/KR100399765B1/ko not_active Expired - Lifetime
- 1998-06-26 IL IL13276198A patent/IL132761A0/xx not_active IP Right Cessation
- 1998-06-26 CZ CZ0474099A patent/CZ297244B6/cs not_active IP Right Cessation
- 1998-06-26 NZ NZ500994A patent/NZ500994A/en not_active IP Right Cessation
- 1998-06-26 PT PT98936392T patent/PT994880E/pt unknown
- 1998-06-26 ID IDW991682A patent/ID24897A/id unknown
- 1998-06-26 BR BR9810956-1A patent/BR9810956A/pt not_active Application Discontinuation
- 1998-06-26 DE DE69828692T patent/DE69828692T2/de not_active Expired - Lifetime
- 1998-06-26 DK DK98936392T patent/DK0994880T3/da active
- 1998-06-26 EP EP98936392A patent/EP0994880B1/en not_active Expired - Lifetime
- 1998-06-26 PL PL336719A patent/PL192761B1/pl unknown
- 1998-06-26 JP JP50628799A patent/JP3880634B2/ja not_active Expired - Lifetime
- 1998-06-26 SK SK1866-99A patent/SK285665B6/sk not_active IP Right Cessation
- 1998-06-26 PE PE1998000568A patent/PE97699A1/es not_active IP Right Cessation
- 1998-06-29 ZA ZA985655A patent/ZA985655B/xx unknown
- 1998-06-29 MY MYPI98002955A patent/MY118718A/en unknown
- 1998-07-21 TW TW087111867A patent/TW552264B/zh not_active IP Right Cessation
-
1999
- 1999-12-02 NO NO19995909A patent/NO312765B1/no not_active IP Right Cessation
-
2000
- 2000-10-17 US US09/690,404 patent/US6423722B1/en not_active Expired - Lifetime
-
2006
- 2006-03-01 JP JP2006055107A patent/JP4504323B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR017754A1 (es) | Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento | |
| CO5310550A1 (es) | Nuevo derivado de androstano antiinflamatorio, su polimorfo, sus formas cristalinas solvatadas, composiciones farmaceutias, proceso para prepararlo, intermediario | |
| BR9803179A (pt) | Antagonistas receptores de ccr-3. | |
| GT200100095A (es) | Metodo de cristalizacion reactiva para mejorar el tamaño de particula. | |
| AR002705A1 (es) | Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen. | |
| AR029312A1 (es) | Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh, procesos para su produccion, formulacion farmaceutica, y uso de estos compuestos para la elaboracion de un medicamento. | |
| GT198304062A (es) | Derivado epimerico de azahomoeritromicina a e intermedios del mismo | |
| AR005703A1 (es) | Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen | |
| AR025052A1 (es) | Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos. | |
| UY26454A1 (es) | Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida | |
| NO881933L (no) | Orale administreringsformer med forsinket avgivning. | |
| AR029570A1 (es) | Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| AR029571A1 (es) | Nueva forma cristalina beta de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| BR0008011A (pt) | Agente embranquecedor fluorescente, suapreparação e uso | |
| UY27410A1 (es) | Formas novedosas crudas cristalinas | |
| CL43546B (es) | Compuesto derivado de tetrahidroquinolina con actividad moduladora del receptor fsh; composicion farmaceutica que contiene al compuesto; y uso del compuesto en la preparacion de medicamentos para la regulacion de la fertilidad. | |
| BR0109508A (pt) | Forma ii, cristalina, de cabergolina | |
| PE79799A1 (es) | Forma cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida | |
| AR035553A1 (es) | Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos. | |
| ECSP982561A (es) | Macrolidas cristalinas | |
| EP0443957A3 (en) | New 17-spiro substituted steroid compounds, process for their preparation and intermediates of this process, their use as medicines and pharmaceutical preparations containing them | |
| ECSP034533A (es) | Derivados sustituyentes 5-amino-1 penteno-3-ol | |
| UY26251A1 (es) | Forma cristalina iii de la n- (4-(5- dimetilaminonaftalen-1- sulfonilamino) fenil) -3 - hidroxi-2, 2- dimetilpropionamida | |
| BR9905904A (pt) | Compostos espiro imidazolina, um processo para a sua preparação e composições farmacêuticas contendo os mesmos | |
| ES2112597T3 (es) | Nuevos derivados de 17-(3-imino-2-alquil-propenil)-5beta,14beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |